Dart Therapeutics: Backed By Non-Profits, Open To Venture
This article was originally published in Start Up
Executive Summary
Dart Therapeutics is owned and funded by rare disease patient foundations, and tiny ones at that. But with its first candidate, for Duchenne muscular dystrophy, it has created a special ownership structure to move the program forward. That takes a page from the recent private investor playbook, and Dart’s CEO wants to use venture capital to fund more programs without losing its patient-centric vision and grassroots passion.
You may also be interested in...
Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
Partnering Door Opens For Sarepta With 48-Week Data In Hand
Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.
Series A Financing For Annovation Includes Potential Buyout By TMC
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.